Fluticasone furoate/umeclidinium/vilanterol

Drug Profile

Fluticasone furoate/umeclidinium/vilanterol

Alternative Names: Closed Triple; FF/UMEC/VI; Fluticasone Furoate/Umeclidinium/Vilanterol Trifenatate; Fluticasone furoate/vilanterol/umeclidinium; GSK 2834425; GW 685698/GSK 573719/GW 642444; ICS/LABA/LAMA - GSK; ICS/LAMA/LABA - GSK; UMEC/VI/FF; Umeclidinium/fluticasone furoate/vilanterol; Umeclidinium/vilanterol/fluticasone furoate; Vilanterol/fluticasone furoate/umeclidinium; Vilanterol/umeclidinium/fluticasone furoate

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline; Theravance
  • Developer GlaxoSmithKline
  • Class Androstadienes; Benzhydryl compounds; Bronchodilators; Chlorobenzenes; Ethers; Glucocorticoids; Phenols; Quinuclidines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Chronic obstructive pulmonary disease
  • Phase III Asthma

Most Recent Events

  • 22 Jun 2017 GlaxoSmithKline initiates a long-term safety, phase III trial for Asthma in Japan (NCT03184987)
  • 16 Jun 2017 GlaxoSmithKline plans a phase III trial for Asthma (NCT03184987)
  • 23 May 2017 GlaxoSmithKline completes a phase IIIb trial for Chronic obstructive pulmonary disease in Argentina, Australia, France, Germany, Italy, Japan, South Korea, Poland, Russia, Romania, Spain and Mexico (Inhalation) (NCT02729051)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top